What Are CHO Cells? The Unsung Heroes of Biologic Drug Production

Chinese Hamster Ovary (CHO) cells are often referred to as the unsung heroes of biologic drug production. These adaptable and efficient cells have carved out a niche as the preferred platform for manufacturing complex biologics, including antibodies, hormones, and vaccines. The pivotal role they play in biotechnology cannot be overstated, yet they often remain in the shadows of the final product that reaches patients around the globe.

CHO cells are derived from the ovary of the Chinese hamster and have been used in scientific research since the 1960s. Their rise to prominence in the pharmaceutical industry is largely due to their unique characteristics, which make them ideally suited for large-scale production of biologics. One of their most significant advantages is their ability to grow in suspension cultures, which allows for easy scaling up of production processes in bioreactors. Furthermore, CHO cells can thrive in serum-free media, reducing the risk of contamination with animal-derived pathogens.

The adaptability of CHO cells is another compelling reason for their widespread use. These cells can be genetically modified to produce a wide variety of proteins, which is crucial for the development of biologics. This flexibility is complemented by their ability to perform complex post-translational modifications, such as glycosylation, which are essential for the efficacy and stability of many therapeutic proteins. The glycosylation patterns in CHO cells are similar to those in humans, making them an excellent choice for producing proteins with human-like characteristics.

In addition to their practical advantages, CHO cells have a well-established safety profile. Over decades of use in research and drug production, they have consistently demonstrated low risk of introducing harmful viruses or other pathogens into the final product. This, combined with extensive regulatory acceptance, has solidified their position as the gold standard in biologic manufacturing.

The production of biologics using CHO cells involves a complex and highly controlled process. It begins with the insertion of a gene of interest into the CHO cells, which are then cultured to produce the desired protein. These proteins are harvested and undergo rigorous purification processes to ensure their safety and efficacy. The final biologic product must meet stringent regulatory standards before it can be used in clinical settings.

While CHO cells have been a cornerstone of biologic drug production for several decades, research continues to enhance their capabilities. Scientists are constantly developing new techniques to improve the yield and quality of proteins produced by CHO cells. Advances in genetic engineering, for example, have enabled the development of new CHO cell lines with enhanced productivity and stability. Such innovations promise to further cement the role of CHO cells in the future of biologic drug manufacturing.

In conclusion, CHO cells are integral to the production of modern biologics, offering unparalleled advantages in terms of scalability, safety, and adaptability. Their contributions to healthcare have been invaluable, enabling the development of a wide array of life-saving therapeutics. As biotechnology continues to evolve, the legacy of CHO cells as the workhorses of biologic production will undoubtedly endure, bringing hope and healing to patients around the world.

For an experience with the large-scale biopharmaceutical model Hiro-LS, please click here for a quick and free trial of its features！